Generic drug development runs on borrowed science. The molecule has already been discovered, the clinical benefit already proven. The scientific […]

The active pharmaceutical ingredient gets the press release. Excipients get the patent that keeps generic companies out for a decade.

Target Audience: Pharma/biotech IP counsel, ANDA portfolio managers, R&D leads, CMC directors, and institutional investors tracking complex generics pipelines. 1.

Generic drugs account for 91% of all U.S. prescriptions dispensed while consuming less than 20% of total drug spend. That

Pharmaceutical Licensing Agreements: The Complete IP Valuation, Deal Architecture, and Strategy Guide for Pharma/Biotech Leaders Pharmaceutical licensing is, at its

1. Scale and Economics: What AI Actually Costs and What It Might Deliver The pharmaceutical industry’s standard development timeline averages

The expiration of primary patents on high-value therapeutics, frequently termed the patent cliff, creates a predictable revenue vacuum for innovators.

Patent opposition is where pharma IP stops being administrative paperwork and starts functioning as competitive strategy. A single successful opposition